Autism is a highly prevalent neurodevelopmental disorder of genetics origins with potentially devastating effects for child and family, and with a societal cost of 35 to 80 billion dollars per year. To capitalize on early neuroplasticity, our goal is to perfect devices for the detection of autism in early infancy and to deploy them in the community for universal screening in babies. By tying screening to early treatments and intervention, we aim to develop a new model of health care delivery for children with autism. In a parallel effort, we are examining the instantiation of genetic vulnerabilities in autism through studies attempting to bridge molecular genetics and social development in both human infants and non-human primates. A better mapping of genetically-driven pathways on foundational mechanisms of sociability in infancy carries the hope of novel treatments for attenuating or preventing this condition.